Get Premium to unlock powerful stock data
NAS:AVIR (USA)  
Atea Pharmaceuticals Inc logo

Atea Pharmaceuticals Inc

$ 7.46 +0.16 (+2.19%) 03:27 PM EST
P/E:
14.26
P/B:
0.89
Market Cap:
$ 616.94M
Enterprise V:
$ -94.89M
Volume:
216.85K
Avg Vol (2M):
866.04K
Volume:
216.85K
Market Cap $:
616.94M
PE Ratio:
14.26
Avg Vol (2-Month):
866.04K
Enterprise Value $:
-94.89M
PB Ratio:
0.89
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Atea Pharmaceuticals Inc
NAICS : 541714 SIC : 2833
125 Summer Street, Boston, MA, USA, 02110
Description
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.
Name Current Vs Industry Vs History
Cash-To-Debt 245.32
Equity-to-Asset 0.95
Debt-to-EBITDA 0.04
Interest Coverage N/A
N/A
N/A
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 11.65
Distress
Grey
Safe
Beneish M-Score 5.23
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year FCF Growth Rate -76

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 63.2
9-Day RSI 55.98
14-Day RSI 53.62
6-1 Month Momentum % -17.45
12-1 Month Momentum % -65.4

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 24.93
Quick Ratio 24.93
Cash Ratio 24.66
Days Sales Outstanding 63.95

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -23.9

Financials (Next Earnings Date:2022-08-12 Est.)

AVIR's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:AVIR

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 285.382
EPS (TTM) ($) 0.51
Beta 0
Volatility % 96.98
14-Day RSI 53.62
14-Day ATR ($) 0.444705
20-Day SMA ($) 7.1945
12-1 Month Momentum % -65.4
52-Week Range ($) 5.31 - 46.9099
Shares Outstanding (Mil) 83.26

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Atea Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More